BPC-157 / TB-500 (Wolverine)
BPC-157 + TB-500 research blend
Research blend name for BPC-157 + TB-500; one 2026 rat tendon study tested the combination directly, but no controlled human blend trial has established efficacy or dosing.
Reference dose
BPC-157 250–500 mcg daily + TB-500 1–2.5 mg 2–3× weekly
Source-specific educational reference, not an individualized recommendation.
Reference schedule
Mixed by component · 4–6 weeks
New to peptide research?
This page gets detailed quickly.
Profiles include evidence, formats, units, source-specific reference amounts and, where relevant, device details. If any of those terms are unfamiliar, do not guess your way through them. Start with a Personalised Guide and we will put the foundations in the right order for you.
At a glance
Components
2 peptides
BPC-157 + TB-500.
Direct blend evidence
1 rat study
Published in 2026 in an Achilles tendon repair model.
Human blend trials
None identified
The direct combination evidence remains preclinical.
Synergy demonstrated
No
The 2026 study found no added benefit over either agent alone.
What it is
Wolverine is a community/vendor name for a research combination of BPC-157 and TB-500.
The two peptides remain separate molecules with different research histories; the blend name does not represent a newly characterized pharmaceutical entity.
Research focus
How it works
Wolverine combines BPC-157 and TB-500, two research compounds associated with different tissue-repair pathways. A 2026 rat Achilles-tendon study tested the combination directly, but it did not show added benefit over the single-agent groups and cannot establish human efficacy.
Important context
Wolverine is the only one of these three blend profiles with a direct published combination experiment identified in this rollout. That study was in 32 rats after Achilles tendon transection and repair, not in humans, and the authors concluded that combined BPC-157 + TB-500 did not confer additional benefit over either peptide alone.
What it is studied for
The combination is intended to bring together two preclinical tissue-repair research themes: BPC-157-related vascular/connective-tissue biology and thymosin-beta-4-related cytoskeletal/repair biology.
A direct 2026 rat tendon study tested whether concurrent treatment improved healing compared with either component alone.
The study did not establish additive benefit, making it especially important not to present the blend as inherently superior to the components.
More contextDirect combination evidence exists, but it is still preclinicalSee the deeper context, evidence details and practical distinctions behind this profile.
The 2026 rat study compared control, BPC-157, TB-500 and combination groups over four weeks. Some histopathological measures improved in the treatment groups, while TB-500 alone showed the clearest biomechanical advantage.
The combination did not outperform either component alone. This directly challenges the common assumption that putting both compounds together necessarily creates synergy.
- The study used 32 male Sprague-Dawley rats, eight per group, with intraperitoneal dosing after surgical Achilles tendon repair.
- The combination improved one histopathological score versus control but did not show added benefit over either single-agent group.
- No controlled human trial of the BPC-157 + TB-500 blend was identified for this profile.
- BPC-157 and TB-500 still retain the major human-evidence and regulatory limitations described on their individual profiles.
Why people are interested
What makes BPC-157 / TB-500 (Wolverine) worth researching.
Direct blend evidence · animal
Direct tendon-combination study
A 2026 rat Achilles-tendon repair experiment directly compared BPC-157, TB-500, the combination and control.
Direct blend evidence · animal
No demonstrated additive benefit
Although some treatment groups improved on histological measures, the authors concluded that combined BPC-157 + TB-500 did not provide additional benefit over either component alone.
Component · mostly preclinical
BPC-157 component evidence
The broader BPC-157 literature remains dominated by animal studies, with only very limited human pilot evidence.
Component · preclinical / indirect
TB-500 component evidence
TB-500 is a thymosin-beta-4 fragment with no established human drug-exposure dataset identified by FDA; full-length thymosin-beta-4 data are indirect.
Evidence
Where the evidence is strongest, and what kind of evidence it is.
Animal · randomized four-group experiment
2026 Achilles tendon study
Thirty-two rats were allocated to control, BPC-157, TB-500 or combination treatment after Achilles tendon transection and repair. The combination improved some histology versus control but did not outperform single agents.
Animal · direct comparison
Biomechanical result
TB-500 alone was the only group with a statistically significant maximum-load-to-failure advantage versus control in the reported pairwise analysis.
Not established
Human combination evidence
No controlled human trial of the BPC-157 + TB-500 blend was identified for this profile.
FDA compounding review · 2026
Regulatory context
BPC-157-related and TB-500-related bulk substances were both reviewed by FDA's Pharmacy Compounding Advisory Committee process.
Human research
No controlled human clinical trial of the Wolverine BPC-157 + TB-500 blend was identified for this profile.
BPC-157 has very limited published human pilot data, while FDA reports no identified human drug-exposure data for the TB-500 fragment.
Those component-level human evidence gaps remain even though a direct animal combination study now exists.
Preclinical research
A 2026 Achilles-tendon repair study in 32 rats directly evaluated BPC-157, TB-500 and their combination.
The study reported improvements in several histological measures in treatment groups, with TB-500 alone also showing a significant biomechanical advantage versus control.
The authors explicitly concluded that combined treatment did not confer additional benefits compared with either agent alone.
Reference dosing
Reference amount, schedule and conversion.
A reference amount is only useful when you know the formulation, concentration and delivery device it belongs to. Do not transfer a vial amount into a pen, a pen click count into another pen, or a syringe-unit number into a different concentration.
01
Identify the format
Vial, reusable cartridge pen, prefilled multi-dose pen or single-dose autoinjector.
02
Confirm concentration
Know the total peptide amount and liquid volume or the manufacturer/vendor concentration.
03
Understand the units
Keep mg/mcg, mL and syringe units or device clicks separate.
04
Then use the reference
Only convert a known reference amount with the calculator that matches the actual device.
Source-specific reference
BPC-157 250–500 mcg daily + TB-500 1–2.5 mg 2–3× weekly
Mixed by component · 4–6 weeks
The component amounts above are the Pep Report research reference for the BPC-157 / TB-500 combination. Commercial ratios can vary, so confirm both component amounts before calculating concentration.
Calculator connection
This profile does not currently use a vial or pen calculator. Follow the formulation-specific information shown for the product or reference you are using.
A two-peptide blend requires the exact mass of BPC-157 and TB-500 to calculate each component concentration. Total vial mg alone can hide very different ratios, so the generic single-peptide vial calculator is disabled.
Storage
Start with the format. Then verify the exact product.
Rule of thumb, not a product instruction
Storage belongs to the exact formulation. Generic advice can orient you, but the label, pharmacy directions or formulation-specific stability data should determine the final temperature and usable-life limits.
Pens
Treat a pen as a finished drug-device product: protect it from unnecessary heat and light, do not freeze unless the exact label explicitly permits it, and use that device's own unopened and in-use storage window.
Vials
Treat dry and reconstituted vials as different stability states. Refrigeration after mixing is common for some formulations but is not a universal peptide rule.
Product-specific notes
There is no approved Wolverine product label establishing standardized storage or stability conditions.
Co-formulated vial stability may depend on exact peptide forms, ratio, excipients and handling.
Practical reference
Formats
Two-peptide blend vial
Reconstitution & units
Adding liquid changes both BPC-157 and TB-500 concentrations at the same time.
The exact mass of each component is required to calculate each component concentration; total blend mg alone is insufficient.
The generic single-peptide vial calculator is disabled because it cannot represent two separate peptide masses.
A future blend calculator should require separate BPC-157 and TB-500 vial amounts before displaying component-level concentration arithmetic.
Safety, status & open questionsOpen the practical cautionsWolverine is not an FDA-approved medicine. There is now direct animal combination evidence, but it does not establish synergy, human benefit, a clinically validated ratio or a safe human dosing schedule.
Open questions
The rat combination study does not establish human efficacy, dose, route, ratio or long-term safety.
Wolverine formulations are not standardized and may use different BPC-157:TB-500 mass ratios.
Human pharmacokinetics and interaction effects for the co-formulation are unknown.
It is not established whether co-lyophilization or shared reconstitution changes the stability or activity of either component.
Regulatory notes
Wolverine is not an FDA-approved drug or standardized pharmaceutical formulation.
BPC-157-related and TB-500-related bulk substances were both considered in FDA's July 2026 Pharmacy Compounding Advisory Committee review.
Neither component has an FDA-approved human indication corresponding to the recovery claims commonly made for the blend.
Practical notes
There is no direct controlled human safety dataset for the Wolverine blend.
BPC-157 and TB-500 each have major human-evidence gaps, and those uncertainties persist when they are combined.
Research/compounded injectable products add risks around sterility, identity, purity and concentration.
Unknown blend stability and interaction effects create additional uncertainty beyond the individual component profiles.
Common mistakes
Calling the 2026 rat study proof that Wolverine works in humans.
Claiming synergy when the direct animal study did not show added benefit over either component alone.
Quoting a total blend dose without specifying the BPC-157:TB-500 ratio.
Using full-length thymosin-beta-4 human studies as direct evidence for TB-500.
Using a generic one-mass vial calculator for a two-component formulation.
Common questions
Has Wolverine actually been studied as a combination?
Yes, one 2026 rat Achilles-tendon study directly tested BPC-157 + TB-500. It remains preclinical and did not show added benefit over either component alone.
Does that study prove the combination is better?
No. The authors specifically concluded that the combined treatment did not confer additional benefit compared with either agent alone.
Are there controlled human Wolverine trials?
No controlled human blend trial was identified for this profile.
Why is the vial calculator disabled?
Because the current calculator accepts one total peptide mass. A Wolverine vial needs separate BPC-157 and TB-500 masses to calculate component concentrations accurately.
Related peptides & blends
BPC-157
Synthetic 15-amino-acid peptide with extensive animal research in tissue-repair and gastrointestinal models but very limited human evidence.
Open reference →TB-500
Synthetic thymosin-beta-4-related fragment researched for wound and tissue-repair biology, with no established human clinical evidence for the fragment itself.
Open reference →GLOW
Vendor/community blend name for a co-formulation of GHK-Cu, BPC-157 and TB-500; evidence comes from the individual components rather than the three-peptide blend itself.
Open reference →KLOW
Four-peptide research blend combining GHK-Cu, BPC-157, TB-500 and KPV; the evidence base belongs to the individual components rather than the co-formulation.
Open reference →References
BPC-157 + TB-500 in rat Achilles tendon healing — direct combination study
Joint Diseases and Related Surgery / PubMed · 2026
BPC-157 in orthopaedic sports medicine — systematic review
PMC · 2025
BPC-157 human IV safety pilot
PubMed · 2025
FDA July 2026 PCAC review — BPC-157 and TB-500-related substances
U.S. FDA · 2026
FDA — compounded bulk substances that may present significant safety risks
U.S. FDA · 2026